“Cetrorelix”的意思、由来-开放百科全书

Cetrorelix ({{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|BAN|British Approved Name}}), or cetrorelix acetate ({{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|JAN|Japanese Accepted Name}}), sold under the brand name Cetrotide, is an injectable gonadotropin-releasing hormone (GnRH) antagonist. A synthetic decapeptide, it is used in assisted reproduction to inhibit premature luteinizing hormone surges^[1] The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, cetrorelix can be used to treat hormone-sensitive cancers of the prostate{{cn|date=January 2016}} and breast (in pre-/perimenopausal women){{cn|date=January 2016}} and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning).{{cn|date=January 2016}} It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; if human chorionic gonadotropin (hCG) is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered.

Medical uses

Cetrorelix is marketed by Merck Serono for use in in-vitro fertilization in all countries except Japan, where it is marketed by Shionogi and Nippon Kayaku.^[2] Aeterna Zentaris receives royalties on these sales and retains rights to develop cetrorelix for other indications. In IVF use it is injected daily after follicle stimulation has been initiated and evidence of follicle maturation is approaching; given daily it prevents an endogenous LH surge that would trigger an untimely ovulation prior to the hCG administration by the treating physician. As an alternative to the GnRH antagonist, also a GnRH agonist could be given, but agonist have to be started earlier to overcome the agonistic effect. Cetrorelix can be mixed with follitropin alpha without compromising their reported safety and efficacy.^[3]

Over a period of 3 weeks, daily injections of cetrorelix were administered to 12 men in order to suppress testosterone levels. Testosterone levels were significantly suppressed as compared to a control group. During this time of suppression, increases in high density lipoproteins (HDLs) were seen. HDLs are responsible for removing cholesterol from the blood and higher amounts are correlated with increased cardiovascular health.^[4]

Contraindications

The use of cetrorelix is contraindicated in severe renal impairment. It is not intended for women aged 65 years or older. Use in women with severe allergic conditions is not recommended. Use with caution in women with active allergies or history of allergies.

Research

Cetrorelix was under development for the treatment of benign prostatic hyperplasia, premenopausal breast cancer, endometriosis, ovarian cancer, prostate cancer, and uterine fibroids, but development for these indications was discontinued.^[5]

A study published in Nature Medicine found a link between hormonal imbalance in the womb and Polycystic ovary syndrome (PCOS), specifically prenatal exposure to anti-Müllerian hormone. ^[6] For the study, the researchers injected pregnant mice with AMH so that they had a higher than normal concentration of the hormone. Indeed, they gave birth to daughters who later developed PCOS-like tendencies. These included problems with fertility, delayed puberty, and erratic ovulation. To reverse it, the researchers dosed the polycystic mice with cetrorelix, which made the symptoms to go away .These experiments should be confirmed in humans, but it could be the first step in understanding the relationship between the polycystic ovary and the anti-Müllerian hormone.

See also

References

1. ^http://www.emdserono.com/ms.country.us/en/images/Cetrotide_PI_tcm115_140012.pdf?Version=
2. ^Aeternia Zentaris product page{{dead link|date=November 2016 |bot=InternetArchiveBot |fix-attempted=yes }}
3. ^{{Cite journal| journal = Fertility and Sterility| title = Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study | first7 = C.| last7 = Tzeng| volume = 94| issue = 1| doi = 10.1016/j.fertnstert.2009.02.062| pmid = 19339001| year = 2010| pages = 179–183 | first6 = J.| last6 = Hwang| last3 = Chang | first2 = Y.| last2 = Wen | first1 = Y. | first3 = Y.| last4 = Seow | first5 = B.| last5 = Hsieh | first4 = K.| last1 = Lin}}
4. ^{{cite journal | author = von Eckardstein, A | title = Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a) | journal = Journal of Clinical Endocrinology | volume = 82 | issue = 10 | date = 1997 | pages = 3367}}
5. ^{{cite web | url=http://adisinsight.springer.com/drugs/800001307 | title=Cetrorelix |work=AdisInsight}}
6. ^{{Cite journal | doi=10.1038/s41591-018-0035-5|pmid = 29760445| pmc=6098696| title=Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood| journal=Nature Medicine| volume=24| issue=6| pages=834–846| year=2018| last1=Tata| first1=Brooke| last2=Mimouni| first2=Nour El Houda| last3=Barbotin| first3=Anne-Laure| last4=Malone| first4=Samuel A.| last5=Loyens| first5=Anne| last6=Pigny| first6=Pascal| last7=Dewailly| first7=Didier| last8=Catteau-Jonard| first8=Sophie| last9=Sundström-Poromaa| first9=Inger| last10=Piltonen| first10=Terhi T.| last11=Dal Bello| first11=Federica| last12=Medana| first12=Claudio| last13=Prevot| first13=Vincent| last14=Clasadonte| first14=Jerome| last15=Giacobini| first15=Paolo}}